By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
PreferencesDenyAccept

Neuro-Immune Pipeline:

The Doloromics pipeline is built upon our proprietary discovery and validation platform DOLOReS. Through our human-first approach, we are ensuring that we prosecute targets directly implicated by data derived from human disease patients and the mechanistic signatures driving their condition.
right arrow
Learn more

Therapeutic Pipeline:

Program
Program
Preclinical
Hit ID
Lead Gen.
Lead Opt.
IND Enablement
Phase 1
Phase 2
Indication
Indication
Dolo-3.1
Dolo-3.1
58
Cytokine
Monoclonal Antibody
Preclinical
Hit ID
Lead Gen.
Lead Opt.
IND Enablement
Phase 1
Phase 2
IBD
IBD
Dolo-4.2
Dolo-4.2
35
GPCR
Small Molecule
Preclinical
Hit ID
Lead Gen.
Lead Opt.
IND Enablement
Phase 1
Phase 2
Neuroprotection
Neuroprotection
Dolo-0.2
Dolo-0.2
15
Ion Channel Auxiliary Protein
Small Molecule
Preclinical
Hit ID
Lead Gen.
Lead Opt.
IND Enablement
Phase 1
Phase 2
Epilepsy
Epilepsy
Dolo-2.1
Dolo-2.1
50
Growth Factor
Monoclonal Antibody
Preclinical
Hit ID
Lead Gen.
Lead Opt.
IND Enablement
Phase 1
Phase 2
Partnered
Partnered

Our Commitment is to Patients and Caregivers:


Doloromics is bringing precision medicine to diseases hallmarked by neuronal hyperexcitability. We believe therapeutic treatments should be bespoke to individual diseases.


right arrow
Learn more
Precision | Human | Development
right arrow
Learn more
Privacy PolicyTerms of ServiceCookie PolicyCookies Settings